**GORE® TAG®**
Conformable Thoracic Endoprosthesis

# Your commitment to quality of care is one we proudly share

That's why we created **GREAT**, the Global Registry for Endovascular Aortic Treatment, to evaluate real-world performance and inform future clinical practice.

Over a decade in the making.
Nearly 5,000 patients.
Over 30 publications.

**5-YEAR TEVAR UPDATE**

## Evidence with real-life relevance

| | |
|---|---|
| LARGE COHORT | **578 TEVAR patients treated** with the GORE® TAG® Conformable Thoracic Endoprosthesis |
| LONG TERM | 10-year follow-up planned |
| REAL-WORLD POPULATION* | 44% off-label TEVAR cases[1] |

> "GREAT provides a picture of the real-world use of [GORE® TAG® Conformable Thoracic Endoprosthesis] in TEVAR for the treatment of multiple thoracic aortic pathologies."

| Ascending arch | Type B dissection | Descending thoracic aortic aneurysm |
|---|---|---|
| 4.5% | 35.1% | 41.3% |
| n = 26 | n = 203 | n = 239 |

See the data

* Age requirement and indication for aortic stent graft repair as determined by the treating physician.

*Together, improving life*

# Durable performance across thoracic dissection and aneurysmal pathologies

Through 5 years, the GORE® TAG® Conformable Thoracic Stent Graft showed sustained safety and efficacy in real-world practice.[1]

## GREAT outcomes at-a-glance

### ZERO

Fractures

Device compressions

### FAVORABLE

Freedom from all-cause mortality

Aortic-related mortality

Procedure survival 99.7%

### LOW RATES[1]

Stroke

Paralysis

Reintervention

Serious TYPE III endoleaks*

Migration†

**All-cause mortality by pathology**




**Aortic-related mortality by pathology**




An endovascular approach for treatment of all thoracic aortic pathologies using the [GORE® TAG® Conformable Thoracic Endoprosthesis] can be accomplished in a "real-world" setting with low peri-procedural risk and a favorable freedom from aortic-related mortality long-term through 5 years.[1]

* Only serious endoleaks are reported in GREAT (i.e., those meeting the ISO141155 definition of a Serious Adverse Event).

† Only 1 device migration was seen over this time frame.

# We build evidence, so you can build confidence

Designed to reflect real-world use, GREAT enriches the evidence at your disposal.

The current study reports a large cohort of thoracic pathology outcomes for TEVAR of up to 60 months. This data fills a gap of knowledge on long-term outcomes to date for this patient population over a long follow-up period, supporting ongoing use of endovascular therapy.[1]

**Access data**

## References

1. Gable DR, Verhoeven E, Trimarchi S, *et al.*; GREAT Investigators. Endovascular treatment for thoracic aortic disease from the Global Registry for endovascular aortic treatment. *Journal of Vascular Surgery* 2024;79(5):11044-1056.e1.

Consult Instructions for Use
**eifu.goremedical.com**

**INDICATIONS FOR USE IN THE U.S.:** The GORE® TAG® Thoracic Stent Graft is intended for endovascular repair of all lesions of the descending thoracic aorta, including: Isolated lesions in patients who have appropriate anatomy, including: adequate iliac/femoral access, aortic inner diameter in the range of 16–42 mm, ≥ 20 mm non-aneurysmal aorta proximal and distal to the lesion; Type B dissections in patients who have appropriate anatomy, including: adequate iliac/femoral access, ≥ 20 mm landing zone proximal to the primary entry tear; proximal extent of the landing zone must not be dissected, diameter at proximal extent of proximal landing zone in the range of 16–42 mm. **CONTRAINDICATIONS:** Patients with known sensitivities or allergies to the device materials; patients who have a condition that threatens to infect the graft. Refer to *Instructions for Use* at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. ℞ Only

Products listed may not be available in all markets.

GORE, Together, improving life, TAG and designs are trademarks of W. L. Gore & Associates, Inc.
© 2024 W. L. Gore & Associates, Inc. 24AR1002-EN AUGUST 2024

**W. L. Gore & Associates, Inc.**
goremedical.com

**Asia Pacific** +65 67332882 **Australia/New Zealand** 1800 680 424 **Europe** 00800 6334 4673
**United States** Flagstaff, AZ 86004 800 437 8181 928 779 2771

GORE